MYNZ vs. CNTX, GRFS, LVTX, NLSP, PHVS, PROC, QLI, TLSA, ATNFW, and SXTPW
Should you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Context Therapeutics (CNTX), Grifols (GRFS), LAVA Therapeutics (LVTX), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), Procaps Group (PROC), Qilian International Holding Group (QLI), Tiziana Life Sciences (TLSA), 180 Life Sciences (ATNFW), and 60 Degrees Pharmaceuticals (SXTPW). These companies are all part of the "medical" sector.
Context Therapeutics (NASDAQ:CNTX) and Mainz Biomed (NASDAQ:MYNZ) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking.
In the previous week, Context Therapeutics had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Context Therapeutics and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.67 beat Context Therapeutics' score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media.
Context Therapeutics has a net margin of 0.00% compared to Context Therapeutics' net margin of -2,934.82%. Mainz Biomed's return on equity of -115.50% beat Context Therapeutics' return on equity.
Context Therapeutics has higher earnings, but lower revenue than Mainz Biomed. Context Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.
Context Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 183.69%. Mainz Biomed has a consensus target price of $6.00, indicating a potential upside of 590.45%. Given Context Therapeutics' higher possible upside, analysts plainly believe Mainz Biomed is more favorable than Context Therapeutics.
Context Therapeutics has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.
14.0% of Context Therapeutics shares are owned by institutional investors. 9.4% of Context Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Mainz Biomed received 3 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 76.47% of users gave Mainz Biomed an outperform vote while only 58.82% of users gave Context Therapeutics an outperform vote.
Summary
Context Therapeutics beats Mainz Biomed on 12 of the 17 factors compared between the two stocks.
Get Mainz Biomed News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mainz Biomed Competitors List
Related Companies and Tools
